S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Something is Coming for America's Top Stock (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Something is Coming for America's Top Stock (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Something is Coming for America's Top Stock (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Something is Coming for America's Top Stock (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Something is Coming for America's Top Stock (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Something is Coming for America's Top Stock (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Something is Coming for America's Top Stock (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Something is Coming for America's Top Stock (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Something is Coming for America's Top Stock (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Something is Coming for America's Top Stock (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Something is Coming for America's Top Stock (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Something is Coming for America's Top Stock (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NYSE:IKT

Inhibikase Therapeutics (IKT) Stock Forecast, Price & News

$1.39
-0.05 (-3.47%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.36
$1.49
50-Day Range
$1.01
$2.60
52-Week Range
$0.95
$6.94
Volume
34,349 shs
Average Volume
76,728 shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00

Inhibikase Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,842.4% Upside
$27.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.39) to ($4.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars


IKT stock logo

About Inhibikase Therapeutics (NYSE:IKT) Stock

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

IKT Price History

IKT Stock News Headlines

Inhibikase Therapeutics (NYSE:IKT) Trading Down 3.5%
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Inhibikase Therapeutics (IKT) Gets a Hold from JonesTrading
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Q2 2023 Inhibikase Therapeutics Inc Earnings Call
See More Headlines
Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IKT Company Calendar

Last Earnings
8/14/2023
Today
10/01/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+1,842.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-18,050,000.00
Net Margins
-7,551.59%
Pretax Margin
-7,551.19%

Debt

Sales & Book Value

Annual Sales
$120,000.00
Book Value
$4.50 per share

Miscellaneous

Free Float
4,262,000
Market Cap
$7.44 million
Optionable
Not Optionable
Beta
0.79
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Milton H. Werner Ph.D. (Age 59)
    CEO, Pres & Director
    Comp: $658.19k
  • Mr. Joseph Frattaroli CPA (Age 61)
    Chief Financial Officer
    Comp: $531.83k
  • Dr. Roger Rush
    Head of Preclinical Research
  • Dr. Surendra Singh
    Head of Chemistry, Manufacturing & Controls
  • Dr. Charles Warren Olanow B.Sc.
    F.R.C.P.C., M.D., CEO of Clintrex Research Corp. & Member of Scientific Advisory Board
  • Dan Williams
    Controller













IKT Stock - Frequently Asked Questions

Should I buy or sell Inhibikase Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IKT shares.
View IKT analyst ratings
or view top-rated stocks.

What is Inhibikase Therapeutics' stock price forecast for 2023?

2 Wall Street analysts have issued 1-year price objectives for Inhibikase Therapeutics' stock. Their IKT share price forecasts range from $27.00 to $27.00. On average, they expect the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 1,842.4% from the stock's current price.
View analysts price targets for IKT
or view top-rated stocks among Wall Street analysts.

How have IKT shares performed in 2023?

Inhibikase Therapeutics' stock was trading at $3.00 on January 1st, 2023. Since then, IKT stock has decreased by 53.7% and is now trading at $1.39.
View the best growth stocks for 2023 here
.

When is Inhibikase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our IKT earnings forecast
.

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) posted its quarterly earnings results on Monday, August, 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.19. The company had revenue of $0.12 million for the quarter. Inhibikase Therapeutics had a negative net margin of 7,551.59% and a negative trailing twelve-month return on equity of 83.69%.

When did Inhibikase Therapeutics' stock split?

Shares of Inhibikase Therapeutics reverse split before market open on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Inhibikase Therapeutics IPO?

(IKT) raised $15 million in an IPO on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is Inhibikase Therapeutics' stock symbol?

Inhibikase Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "IKT."

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibikase Therapeutics' stock price today?

One share of IKT stock can currently be purchased for approximately $1.39.

How much money does Inhibikase Therapeutics make?

Inhibikase Therapeutics (NYSE:IKT) has a market capitalization of $7.44 million and generates $120,000.00 in revenue each year. The company earns $-18,050,000.00 in net income (profit) each year or ($4.1694) on an earnings per share basis.

How can I contact Inhibikase Therapeutics?

The official website for the company is www.inhibikase.com. The company can be reached via phone at 678-392-3419 or via email at alex.lobo@sternir.com.

This page (NYSE:IKT) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -